On October 19, 2009
Amgen’s Denosumab Delay Not a Deal-Breaker; Cancer Remains the Big Question
The FDA’s complete response letter to Amgen regarding approval of denosumab for postmenopausal osteoporosis was an unpleasant surprise that could have been much worse, but the drug’s biggest test is yet to come when the agency reviews its bids in cancer.
0 Comments